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ABSTRACT
The antimicrobial susceptibility of 68 Staphylococcus
aureus isolates collected during 2004 from milk of cows
affected by subclinicalmastitiswas examined. The anti-
microbial agents tested were the β-lactams, penicillin
G, amoxicillin, ampicillin, cloxacillin, amoxicillin + cla-
vulanate, cephalonium, and cefoperazone; and other
drugs including lincomycin, oxytetracycline, doxycy-
cline, and kanamycin. Minimum inhibitory concentra-
tions recorded show that only certain β-lactamase–re-
sistant penicillins (specifically cloxacillin) or penicillin
combinations (amoxicillin + clavulanate) were consis-
tently effective against Staph. aureus, whereas the
other β-lactam derivatives and drugs from other phar-
macological groups were either moderately effective or
ineffective. Thus, β-lactamase–resistant penicillins are
to be considered the antimicrobial agents of choice for
treatment of bovine mastitis resulting from infection
by Staph. aureus.
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Bovine mastitis is the most costly disease to the dairy
industry worldwide, with losses estimated at 2 billion
dollars per year in the United States alone. These rele-
vant economic losses are attributable to rejected milk,
reduced milk quality, early culling, drug costs, veteri-
nary expenses, and increased labor costs (Hoblet et al.,
1991; Gruet et al., 2001). The disease is the most fre-
quent reason for the use of antimicrobial agents on
dairy farms (Erskine, 2000). Intramammary infection
sustained by Staphylococcus aureus may result in clini-
cal or subclinicalmastitis and is usually associatedwith
increased SCC. Appropriate treatment of mastitis dur-
ing the lactation or dry period is an important compo-
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nent of any mastitis control program, but the outcome
for treatment of mastitis caused by Staph. aureus is
variable and the probability of curing the disease is not
high, primarily because of poor distribution of the drug
in the inflamed udder and the occurrence of staphylo-
cocci resistant to antimicrobial agents (Pyo¨ra¨la¨ and Py-
o¨ra¨la¨, 1994). During lactation, the cure rate of subclini-
cal mastitis ranges widely, and this variability can be
due to the choice of antimicrobial agent as well as to
factors associated with the infected cow and the quar-
ter. Therefore, cure is likely not a random event (Schuk-
ken et al., 1994). Antimicrobial therapy is a primary
tool for controlling staphylococcal mastitis, and antimi-
crobial susceptibility tests can guide the veterinarian
in selecting the most appropriate antimicrobial agent
for treatment of IMI byStaph. aureus.However, despite
a variety of available antimicrobial agents, success in
the treatment of Staph. aureus mastitis, particularly
during lactation, is still very low. In fact, Staph. aureus
pathogens have many characteristics that make them
difficult targets for antimicrobial therapy (Sol et al.,
2000). For example, they can penetrate the phagocytic
cells and survive inside them. This process shields the
pathogens from some of the activity of antimicrobial
agents, even with drugs that can penetrate the cells.
The objective of the present study was to evaluate the
antimicrobial resistance patterns of Staph. aureus iso-
lates collected from IMI in cows from 44 commercial
herds in Italy.
Sixty-eight isolates of Staph. aureus taken from indi-
vidual quarters of 68 cows with subclinical mastitis
were used. The isolates were obtained during 2004,
from milk samples collected from animals belonging to
42 dairy herds from different regions of Italy. Animals
were selected on the basis of having quarter milk SCC
greater than 400,000 cells/mL but no sign of clinical
mastitis. Herds were selected to represent different
prevalences of Staph. aureus IMI, ranging from 1 to
100%. The number of isolates for each herd was deter-
mined according to the number of lactating animals in
each herd: One single isolate was collected from 26
small herds (≤50 lactating cows), 2 isolates were col-
lected from 11 medium-sized herds (≤100 lactating
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cows), and more than 2 isolates were collected from
5 large herds (>100 lactating cows). All isolates were
identified on the basis of morphology, hemolysis pat-
tern, and gram staining. The gram-positive cocci were
tested for catalase and coagulase production. The spe-
cies were identified by biochemical tests and by the API
Staph System (BioMe´rieux, Rome, Italy) and were then
stored at −70°C in a nutrient broth enriched with
15% glycerol.
In the present study, the antibiotics were selected
by considering the approved and most frequently used
drugs for the treatment of bovine IMI in Italy, even
if these drugs were not representative of a particular
antibiotic class. The antimicrobial agents selected and
provided by manufacturers as powders were penicillin
G (PEN), ampicillin (AMP), amoxicillin (AMX), AMX
+ clavulanate, cloxacillin (CLX), cephalonium (CFL)
and cefoperazone (CFP), kanamycin, oxytetracycline,
doxycycline, and lincomycin (LIN). The antimicrobial
agentswere dissolved in suitable solvents tomake stock
solutions and then diluted in sterile distilled water ac-
cording to the methods recommended by the Clinical
Laboratory Standards Institute (2002). Minimum in-
hibitory concentration tests were performed according
to the microdilution broth method, as recommended by
the Clinical Laboratory Standards Institute (2002a),
using U-bottomed 96-well microtiter plates. Serial 2-
fold dilutions of the antimicrobial agents were prepared
starting from the stock solution of each drug. The dilu-
tion schemes differed according to the antimicrobial
agent. Inocula were prepared by diluting an overnight
(16 to 18 h) Mueller–Hinton broth culture in buffered
saline solution to a density of 0.5 on the McFarland
turbidity scale and finally diluting it again 40-fold be-
fore testing. TheMIC was defined as the lowest concen-
tration of the antimicrobial agent at which the bacterial
growth was completely inhibited. A reference strain
(Staph. aureus, ATCC 29213) was inoculated as a con-
trol in each plate. The MIC data were summarized,
calculating the MIC values for which the isolates were
equal to or below 50 and 90% (MIC50 andMIC90, respec-
tively), as well as the minimum and maximum MIC
values (range). Resistance and susceptibility, for most
of the antimicrobial agents tested, were determined
according to Clinical Laboratory Standards Institute
(2002a) MIC breakpoints for veterinary pathogens. The
interpretive criteria, however, were based on MIC data
and drug pharmacokinetic data obtained in humans
(taken from Clinical Laboratory Standards Institute,
2002b). Staphylococcus aureus was also tested for β-
lactamase production by the nitrocefin test (Cefinase,
Becton, Dickinson and Co., Sparks, MD).
Numerous data are available in the literature on the
susceptibility to antimicrobial agents of Staph. aureus
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isolates collected from IMI of dairy cattle (Craven et
al., 1986; Watts and Yancey, 1994; Owens et al., 1997;
Makovec and Ruegg, 2003; Pengov and Ceru, 2003; Ti-
kofsky et al., 2003). Nevertheless, obtaining continually
updated MIC values is important to prevent the use of
ineffective antimicrobial drugs. Table 1 reports MIC50
and MIC90 values of the selected antibiotics against the
Staph. aureus isolates examined in the present study.
All values obtained with the control strain were within
the expected ranges for all antimicrobial agents tested.
Of the 68 isolates evaluated, none were susceptible to
all antibiotics and 64 (94%) were resistant to 3 or more
antimicrobial agents.No isolateswere resistant to CLX.
The β-lactams (penicillins and cephalosporins) are
widely used for intramammary treatment of bovine
mastitis, but in the present experiment we observed a
very poor activity of PEN (MIC50 = 0.5 and MIC90 =
2,000 g/mL). The MIC90 for PEN reported in previous
studies ranged from <0.06 to >100g/mL (DeOliveira et
al., 2000; Erskine et al., 2004). In our study, 47 isolates
(69%) of Staph. aureus were PEN resistant. This pro-
portion was greater than those reported for comparable
studies in Argentina (40%; Gentilini et al., 2000), the
United States (38.4 to 60.9%; Erskine et al., 2002), and
Finland (50%; Myllys et al., 1998), but was lower than
that reported for strains isolated frommammary paren-
chymas of slaughtered dairy cows in Brazil (75%; Costa
et al., 2000). Similarly, in the penicillin group, AMP
and AMX had very poor in vitro activity (MIC50 = 2 and
4 g/mL, and MIC90 = 500 and 1,000 g/mL, respec-
tively), and 100 and 98.5% of the isolates were resistant
to these respective antimicrobial agents. Results from
other studies for MIC90 for AMP differed remarkably
from our findings; they ranged from only 0.5 to 4 g/
mL (Watts and Salmon, 1997; De Oliveira et al., 2000).
This high level of resistance was probably related to
the presence of strong β-lactamase producers among
the tested staphylococcal isolates. The in vitro data
confirmed the influence of β-lactamase production on
the microbial susceptibility to β-lactams in general and
to PEN in particular. In fact, the difference between
MIC50 and MIC90 values, with reference to PEN, AMP,
and AMX, correlates very well with the identification
of 28 β-lactamase–producing isolates (58%). Recalcula-
tion of the MIC90 without these strains yielded values
of 0.5 g/mL for PEN and 4 g/mL for both AMP and
AMX. On the other hand, the β-lactamase–resistant
CLX and amoxicillin + clavulanate (a widely used β-
lactamase inhibitor) were both highly effective, with
MIC50 of 0.25 and 1 to 0.5 g/mL and MIC90 of 0.5 and
8 to 4 g/mL, respectively.
The cephalosporins are usually classified into 3 differ-
ent generations on the basis of their respective antimi-
crobial spectra. In the present study, CFL and CFP
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Table 1. Antimicrobial susceptibility of 68 isolates of Staphylococcus aureus collected from different animals
throughout the lactation1
MIC50 MIC90 Range Breakpoints2 Resistance
Agent (g/mL) (g/mL) (/mL) (g/mL) (%)
PEN 0.5 2,000 0.007 to >2,000 ≥0.25 69.1
AMP 2 500 0.25 to >1,000 ≥0.5 98.5
AMX 4 1,000 0.25 to >1,000 ≥0.5 100
AMC 1/0.53 8/43 0.06/0.03 to 16/8 ≥8/4 20.6
CLX 0.25 0.5 0.06 to 2 ≥4 0
KAN 8 64 2 to 250 ≥64 16.2
OXT 32 500 1 to >500 ≥16 58.8
DOX 8 250 0.5 to 250 ≥16 47.1
CFP 2 16 0.5 to >250 NA —
CFL 0.12 2 0.06 to 15.6 NA —
LIN 4 250 1 to >500 NA —
1MIC50 and MIC90 are the minimum concentrations of the various antimicrobial agents required to inhibit
growth of 50 and 90% of the isolates tested, respectively. PEN = benzylpenicillin; AMP = ampicillin; AMX =
amoxicillin; AMC = AMX + clavulanate; CLX = cloxacillin; KAN = kanamycin; OXT = oxytetracycline; DOX =
doxycycline; CFP = cephoperazone; CFL = cephalonium; and LIN = lincomycin; NA = not available.
2Interpretive criteria based on human data.
3Amoxicillin/clavulanate concentrations.
were included as first-generation (good to excellent ac-
tivity against gram-positive bacteria but strain-depen-
dent gram negative activity) and third-generation
drugs (good to moderate activity against gram-positive
bacteria and good to excellent gram negative activity),
respectively. Cefoperazone and CFL showed antistaph-
ylococcal activity greater than that of the β-lactamase–
sensitive penicillins. Between these 2 drugs, CFL
showed greater efficacy than did CFP (MIC50 = 0.12 vs.
2 g/mL and MIC90 = 2 vs. 16 g/mL, respectively).
These results may indicate that these agents are resis-
tant to β-lactamase, which hydrolyzes penicillins. Lin-
comycin, oxytetracycline, doxycycline, and kanamycin
(selected as representative drugs of the lincosamide,
tetracycline, and aminoglycoside groups, respectively)
hadmoderate to poor activity against the Staph. aureus
isolates tested in the present study, as demonstrated
by MIC values ranging from 1 to >500, 1 to >500, 0.5
to 250, and 2 to 250 g/mL, respectively.
The lincosamide antimicrobial agents (e.g., LIN and
clindamycin) act by inhibiting RNA-dependent bacte-
rial protein synthesis (Yao and Moellering, 1995). Lin-
comycin showed an MIC90 of 250 g/mL, and this value
was greater than those previously found in other coun-
tries. For example, LIN MIC90 ranged from 16.0 to 64
g/mL for isolates from the United States, Ireland, Ice-
land, and Germany and from 1.0 to 8.0 g/mL for iso-
lates from Denmark, England, Norway, Sweden, and
Finland (De Oliveira et al., 2000). The LIN MIC90 value
obtained for the strains tested in this study may be
linked with their carriage of the erm gene, which en-
codes resistance to lincosamides, macrolides, and strep-
togramine B antimicrobial agents (Leclercq and Cour-
valin, 1991). Tetracyclines and aminoglycosides are
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broad-spectrum antibioticswidely used to treat respira-
tory and other diseases in cattle. Because of this wide-
spread use, tetracycline and aminoglycoside resistance,
coded by a wide variety of determinants, was demon-
strated by the highMIC90 observed in the present study.
Several factors other than antimicrobial usage can
influence the overall susceptibility patterns of mastitis
pathogens. Scar tissue in the udders of cattle chroni-
cally infected by Staph. aureus often prevents the pene-
tration of antimicrobial agents (DeOliveira et al., 2000).
Therefore, the general recommendation is to cull all
animals with chronic Staph. aureus IMI. The control
of IMI sustained by Staph. aureus should involve the
best management practices and selective antimicrobial
usage. Unfortunately, most antimicrobial agents used
in veterinary medicine still rely on interpretive criteria
developed for humans, and the validity of these inter-
pretive criteria for categorizing veterinary pathogens
as susceptible or resistant has not been established
(Watts and Yancey, 1994). Currently, only pirlimycin
and a penicillin–novobiocin combination have had in-
terpretive criteria developed usingMIC data generated
with mastitis pathogens. Interpretation of antimicro-
bial susceptibility data for the remaining compounds
relies on interpretive criteria developed with human
data. The interpretive criteria used for categorizing iso-
lates as susceptible or resistant are based on human
data for most of the drugs tested in this study. Thus,
the usefulness of susceptibility data is limited to moni-
toring the percentage of Staph. aureus with MIC above
a threshold value, and these values may not be used to
predict clinical efficacy. The percentage of resistance
data presented in this study was used for comparative
purposes but not as an indicator of the actual resistance
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level. The experimental tests performed showed im-
portant in vitro activity against the Staph. aureus iso-
lates of the majority of antimicrobial agents currently
used in Italy for control of IMI. However, we consider
it necessary to develop new interpretive criteria for
studying specific mastitis pathogens and for predicting
clinical efficacy in all those situations in which, as in
cases of mastitis caused by Staph. aureus, scar tissue
barriers or other pathological or physiological factors
can reduce the in vivo efficacy of the drugs.
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